Amgen Inc. and Ultragenyx Pharmaceutical Inc.: SG&A Spending Patterns Compared

SG&A Spending Patterns: Amgen Inc. vs. Ultragenyx Pharmaceutical Inc.

In the competitive landscape of the pharmaceutical industry, understanding spending patterns is crucial. Amgen Inc., a biotech giant, and Ultragenyx Pharmaceutical Inc., a rising star, showcase contrasting strategies in their Selling, General, and Administrative (SG&A) expenses from 2014 to 2023.

Amgen's SG&A expenses have consistently grown, peaking at approximately $6.2 billion in 2023, reflecting a 31% increase over the decade. This growth underscores Amgen's expansive operational strategies and market dominance. In contrast, Ultragenyx, with a more modest budget, saw its SG&A expenses rise from $10.8 million in 2014 to $310 million in 2023, marking a staggering 2,770% increase. This rapid growth highlights Ultragenyx's aggressive expansion and investment in market penetration.

These spending patterns reveal the strategic priorities of each company, with Amgen focusing on sustaining its market leadership and Ultragenyx investing heavily in growth and innovation.